Sino Biopharmaceutical Limited Financial Statements (SBMFF)
|
|
|
|
Report date
|
|
|
31.12.2019 |
31.12.2020 |
31.12.2021 |
31.12.2022 |
31.12.2023 |
|
31.12.2023 |
|
Currency
|
|
|
CNY |
CNY |
CNY |
CNY |
CNY |
|
CNY |
|
|
Revenue, bln rub |
? |
|
24 234 |
23 647 |
26 861 |
28 780 |
26 199 |
|
|
|
Operating Income, bln rub |
|
|
5 808 |
4 888 |
18 860 |
6 690 |
5 439 |
|
|
|
EBITDA, bln rub |
? |
|
7 366 |
6 991 |
19 874 |
6 691 |
6 979 |
|
|
|
Net profit, bln rub |
? |
|
2 762 |
2 771 |
14 608 |
2 544 |
2 332 |
|
|
|
|
OCF, bln rub |
? |
|
5 325 |
5 325 |
5 366 |
6 265 |
6 066 |
|
|
|
CAPEX, bln rub |
? |
|
1 734 |
1 859 |
1 894 |
1 706 |
1 704 |
|
|
|
FCF, bln rub |
? |
|
3 591 |
3 466 |
3 472 |
4 560 |
4 362 |
|
|
|
Dividend payout, bln rub
|
|
|
819.7 |
1 187 |
938.5 |
1 268 |
632.7 |
|
|
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
|
|
Dividend payout ratio, %
|
|
|
29.7% |
42.8% |
6.42% |
49.8% |
27.1% |
|
|
|
|
OPEX, bln rub |
|
|
14 217 |
14 161 |
17 186 |
16 949 |
15 916 |
|
|
|
Cost of production, bln rub |
|
|
4 926 |
5 182 |
5 332 |
5 796 |
4 990 |
|
|
|
R&D, bln rub |
|
|
2 399 |
2 627 |
3 747 |
4 333 |
4 403 |
|
|
|
Interest expenses, bln rub |
|
|
230.0 |
323.4 |
308.6 |
439.1 |
495.2 |
|
|
|
|
Assets, bln rub |
|
|
58 299 |
47 210 |
60 543 |
64 064 |
63 605 |
|
63 605 |
|
Net Assets, bln rub |
? |
|
31 112 |
16 747 |
30 291 |
29 747 |
30 474 |
|
30 474 |
|
Debt, bln rub |
|
|
8 616 |
14 210 |
12 118 |
13 982 |
12 580 |
|
12 580 |
|
Cash, bln rub |
|
|
19 106 |
16 432 |
15 794 |
16 922 |
14 118 |
|
14 118 |
|
Net debt, bln rub |
|
|
-10 490 |
-2 222 |
-3 677 |
-2 940 |
-1 538 |
|
-1 538 |
|
|
Ordinary share price, rub |
|
|
1.47 |
0.980 |
0.665 |
0.585 |
0.416 |
|
|
|
Number of ordinary shares, mln |
|
|
18 811 |
18 800 |
18 769 |
18 622 |
18 529 |
|
|
|
|
Market cap, bln rub |
|
|
27 652 |
18 424 |
12 481 |
10 894 |
7 708 |
|
0 |
|
EV, bln rub |
? |
|
17 163 |
16 202 |
8 805 |
7 954 |
6 170 |
|
-1 538 |
|
Book value, bln rub |
|
|
8 280 |
14 500 |
28 579 |
27 833 |
29 546 |
|
29 546 |
|
|
EPS, rub |
? |
|
0.15 |
0.15 |
0.78 |
0.14 |
0.13 |
|
|
|
FCF/share, rub |
|
|
0.19 |
0.18 |
0.19 |
0.24 |
0.24 |
|
|
|
BV/share, rub |
|
|
0.44 |
0.77 |
1.52 |
1.49 |
1.59 |
|
|
|
|
EBITDA margin, % |
? |
|
30.4% |
29.6% |
74.0% |
23.2% |
26.6% |
|
|
|
Net margin, % |
? |
|
11.4% |
11.7% |
54.4% |
8.84% |
8.90% |
|
|
|
FCF yield, % |
? |
|
13.0% |
18.8% |
27.8% |
41.9% |
56.6% |
|
|
|
ROE, % |
? |
|
8.88% |
16.5% |
48.2% |
8.55% |
7.65% |
|
0 |
|
ROA, % |
? |
|
4.74% |
5.87% |
24.1% |
3.97% |
3.67% |
|
0 |
|
|
P/E |
? |
|
10.0 |
6.65 |
0.85 |
4.28 |
3.31 |
|
|
|
P/FCF |
|
|
7.70 |
5.32 |
3.59 |
2.39 |
1.77 |
|
|
|
P/S |
? |
|
1.14 |
0.78 |
0.46 |
0.38 |
0.29 |
|
|
|
P/BV |
? |
|
3.34 |
1.27 |
0.44 |
0.39 |
0.26 |
|
0 |
|
EV/EBITDA |
? |
|
2.33 |
2.32 |
0.44 |
1.19 |
0.88 |
|
|
|
Debt/EBITDA |
|
|
-1.42 |
-0.32 |
-0.18 |
-0.44 |
-0.22 |
|
|
|
|
R&D/CAPEX, % |
|
|
138.3% |
141.3% |
197.8% |
254.0% |
258.4% |
|
|
|
|
CAPEX/Revenue, % |
|
|
7.16% |
7.86% |
7.05% |
5.93% |
6.50% |
|
|
|
| Sino Biopharmaceutical Limited shareholders |
